Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.27
-0.03 (-0.27%)
Mar 9, 2026, 3:30 PM EDT - Market open
Keros Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 244.06 | 3.55 | 0.15 | - | 20.1 | Upgrade
|
| Revenue Growth (YoY) | 6774.96% | 2250.99% | - | - | - | Upgrade
|
| Cost of Revenue | 127.14 | 173.63 | 135.26 | 87.27 | 55.14 | Upgrade
|
| Gross Profit | 116.92 | -170.08 | -135.11 | -87.27 | -35.04 | Upgrade
|
| Selling, General & Admin | 46.35 | 40.75 | 34.83 | 27.53 | 21.33 | Upgrade
|
| Operating Expenses | 46.35 | 40.75 | 34.83 | 27.53 | 21.33 | Upgrade
|
| Operating Income | 70.57 | -210.83 | -169.94 | -114.79 | -56.37 | Upgrade
|
| Interest Expense | - | - | - | -0 | -0 | Upgrade
|
| Interest & Investment Income | 24.87 | 23.5 | 14.76 | 3.64 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -0.21 | -0.61 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.54 | 0.28 | 2.4 | 7.08 | -0.38 | Upgrade
|
| EBT Excluding Unusual Items | 94.9 | -187.05 | -152.99 | -104.68 | -56.73 | Upgrade
|
| Merger & Restructuring Charges | -3 | - | - | - | - | Upgrade
|
| Pretax Income | 91.9 | -187.05 | -152.99 | -104.68 | -56.73 | Upgrade
|
| Income Tax Expense | 4.88 | 0.3 | - | - | 2.01 | Upgrade
|
| Net Income | 87.01 | -187.35 | -152.99 | -104.68 | -58.74 | Upgrade
|
| Net Income to Common | 87.01 | -187.35 | -152.99 | -104.68 | -58.74 | Upgrade
|
| Shares Outstanding (Basic) | 37 | 37 | 29 | 25 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 38 | 37 | 29 | 25 | 23 | Upgrade
|
| Shares Change (YoY) | 1.13% | 27.13% | 16.66% | 8.17% | 50.48% | Upgrade
|
| EPS (Basic) | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 | Upgrade
|
| EPS (Diluted) | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 | Upgrade
|
| Free Cash Flow | 105.95 | -162.8 | -126.97 | -71.3 | -63.17 | Upgrade
|
| Free Cash Flow Per Share | 2.80 | -4.35 | -4.31 | -2.83 | -2.71 | Upgrade
|
| Gross Margin | 47.91% | - | - | - | -174.34% | Upgrade
|
| Operating Margin | 28.91% | -5938.96% | -112543.71% | - | -280.46% | Upgrade
|
| Profit Margin | 35.65% | -5277.55% | -101319.21% | - | -292.26% | Upgrade
|
| Free Cash Flow Margin | 43.41% | -4585.91% | -84087.42% | - | -314.29% | Upgrade
|
| EBITDA | 72.08 | -209.6 | -169.13 | -114.12 | -56 | Upgrade
|
| EBITDA Margin | 29.53% | - | - | - | -278.58% | Upgrade
|
| D&A For EBITDA | 1.51 | 1.23 | 0.82 | 0.67 | 0.38 | Upgrade
|
| EBIT | 70.57 | -210.83 | -169.94 | -114.79 | -56.37 | Upgrade
|
| EBIT Margin | 28.91% | - | - | - | -280.46% | Upgrade
|
| Effective Tax Rate | 5.31% | - | - | - | - | Upgrade
|
| Revenue as Reported | 244.06 | 3.55 | 0.15 | - | 20.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.